A Study of IMC-3G3 in Prostate Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01204710
First received: September 16, 2010
Last updated: January 22, 2014
Last verified: January 2014

September 16, 2010
January 22, 2014
October 2010
September 2012   (final data collection date for primary outcome measure)
Progression-free survival (PFS) [ Time Frame: Approximately 21 months ] [ Designated as safety issue: No ]
PFS is measured from randomization to the earliest date of the following events: tumor progression according to RECIST v.1.1, unequivocal evidence of progression by bone scan, clinical progression, or death from any cause.
Same as current
Complete list of historical versions of study NCT01204710 on ClinicalTrials.gov Archive Site
  • Overall survival (OS) [ Time Frame: Approximately 21 months ] [ Designated as safety issue: Yes ]
    Overall survival time is measured as randomization to date of death from any cause.
  • Objective Response Rate (ORR) [ Time Frame: Approximately 21 months ] [ Designated as safety issue: No ]
    Proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR) compared to the total number of participants. Best response is categorized using the Response Evaluation Criteria In Solid Tumors (RECIST) (ver 1.1) guidelines.
  • Prostate Specific Androgen (PSA) response rate [ Time Frame: Approximately 21 months ] [ Designated as safety issue: No ]
    Proportion of participants with a decrease in PSA from pretreatment to any time point, requiring confirmation no less than 3 weeks after the initial suggestion of response and occuring prior to documentation of PD. Additionally, a PSA response rate equal to the proportion of participants with a decrease in PSA from pretreatment to week 12 or earlier for those who discontinue therapy.
  • Summary Listing of Participants Reporting Treatment-Emergent Adverse Events [ Time Frame: Approximately 21 months ] [ Designated as safety issue: Yes ]
    Summary listing of Participants Reporting Treatment-Emergent Adverse Events that received IMC-3G3.
  • Circulating Tumor Cells and PDGFRα expression [ Time Frame: Approximately 21 months ] [ Designated as safety issue: No ]
  • Maximum concentration (Cmax) cycles 1, 2, 3, and 4 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Serum Anti-IMC-3G3 Antibody Assessment (immunogenicity) [ Time Frame: Approximately 21 months ] [ Designated as safety issue: Yes ]
    Screen for the development of circulating antibodies against IMC-3G3
  • Overall survival (OS) [ Time Frame: Approximately 21 months ] [ Designated as safety issue: Yes ]
    Overall survival time is measured as randomization to date of death from any cause.
  • Objective Response Rate (ORR) [ Time Frame: Approximately 21 months ] [ Designated as safety issue: No ]
    Proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR) compared to the total number of participants. Best response is catorgorized using the Response Evaluation Criteria In Solid Tumors (RECIST) (ver 1.1) guidelines.
  • Prostrate Specific Androgen (PSA) response rate [ Time Frame: 21 months ] [ Designated as safety issue: No ]
    Proportion of participants with a decrease in PSA from pretreatment to any time point, requiring confirmation no less than 3 weeks after the initial suggestion of response and occuring prior to documentation of PD. Additionally, a PSA response rate equal to the proportion of participants with a decrease in PSA from pretreatment to week 12 or earlier for those who discontinue therapy.
  • Summary Listing of Participants Reporting Treatment-Emergent Adverse Events [ Time Frame: Approximately 21 months ] [ Designated as safety issue: Yes ]
    Summary listing of Participants Reporting Treatment-Emergent Adverse Events that received IMC-3G3.
  • Circulating Tumor Cells and PDGFRα expression [ Time Frame: Approximately 21 months ] [ Designated as safety issue: No ]
  • Maximum concentration (Cmax) cycles 1, 2, 3, and 4 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Serum Anti-IMC-3G3 Antibody Assessment (immunogenicity) [ Time Frame: Approximately 21 months ] [ Designated as safety issue: Yes ]
    Screen for the development of circulating antibodies against IMC-3G3
Not Provided
Not Provided
 
A Study of IMC-3G3 in Prostate Cancer
A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 Plus Mitoxantrone Plus Prednisone or Mitoxantrone Plus Prednisone in Metastatic Castration-Refractory Prostate Cancer Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy

This is a study evaluating the safety and efficacy of the monoclonal antibody IMC-3G3 plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following disease progression or intolerance on docetaxel-based chemotherapy.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
  • Biological: IMC-3G3
    15mg/kg I.V. Days 1 and 8
    Other Names:
    • Olaratumab
    • LY3012207
  • Drug: Mitoxantrone

    Mitoxantrone 12 mg/m2 I.V. Day 1

    Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m2)

  • Experimental: IMC-3G3 + Mitoxantrone
    1 cycle = 3 weeks (21 days)
    Interventions:
    • Biological: IMC-3G3
    • Drug: Mitoxantrone
  • Active Comparator: Mitoxantrone
    1 cycle = 3 weeks (21 days)
    Intervention: Drug: Mitoxantrone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
123
October 2013
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • histologically-confirmed adenocarcinoma of the prostate
  • radiographic evidence of metastatic prostate cancer (stage M1 or D2)
  • has prostate cancer unresponsive or refractory to medical or surgical castration with a serum testosterone level of < 50 ng/mL
  • has had disease progression or intolerance on docetaxel-based therapy
  • PSA ≥ 10 ng/mL
  • all clinically significant toxic effects of prior surgery, radiotherapy, chemotherapy or hormonal therapy have resolved to ≤ Grade 1, based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.02
  • patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  • adequate hematologic function
  • adequate hepatic function
  • adequate renal function
  • urinary protein is ≤ 1 on dipstick or routine analysis
  • life expectancy of more than 3 months
  • fertile man with partners that are women of childbearing potential must use an adequate method of contraception during the study
  • signed Informed Consent document

Exclusion Criteria:

  • concurrent active malignancy other than adequately treated nonmelanomatous skin cancer or other noninvasive or in situ neoplasms
  • The patient has received more than 1 prior cytotoxic chemotherapy regimen for metastatic disease
  • prior therapy with mitoxantrone for advanced prostate cancer
  • The patient has a history of symptomatic congestive heart failure or has a pre study echocardiogram or multigated acquisition scan with left ventricular ejection fraction that is ≥ 10% below the lower limit of normal institutional range
  • history of prior treatment with other agents that directly inhibit PDGF or platelet-derived growth factor receptors
  • known allergy to any of the treatment components: IMC 3G3, mitoxantrone, and/or prednisone
  • radiotherapy within 21 days prior to first dose of IMC-3G3
  • any investigational therapy within 30 days of randomization
  • is receiving corticosteroids at a dose > 5 mg prednisone orally (PO) 2 times per day (BID) or equivalent
  • received prior strontium-89, rhenium-186, rhenium-188, or samarium-153 radionucleotide therapy and has either ongoing evidence of bone marrow dysfunction or poorly controlled bone pain
  • has any ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, psychiatric illness, active bleeding or pathological condition that carries a high risk of bleeding, or any other serious uncontrolled medical disorders
  • known or suspected brain or leptomeningeal metastases
  • known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Czech Republic,   Germany,   Hungary,   Italy,   Poland,   Spain
 
NCT01204710
13938, I5B-IE-JGDD, CP15-0805, 2009-018015-11
Yes
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP